Rivipansel
As of the edition of 20 October 2026, Rivipansel is a small molecule: stopped in 2019; acts on SELE, SELL and SELP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2019
- Kind
- Small molecule
- Registered trials
- 9, 1 stopped early
- Disease areas
- Blood and lymph; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Rivipansel.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Crescent Biopharma | Lead sponsor of trials | 2009 to now |
| Biossil | Lead sponsor of trials | 2015 to now |